financetom
Business
financetom
/
Business
/
Update: Market Chatter: Meta Buried Evidence Showing Mental Health Damage of Facebook Usage
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Meta Buried Evidence Showing Mental Health Damage of Facebook Usage
Nov 25, 2025 12:36 AM

03:26 AM EST, 11/25/2025 (MT Newswires) -- (Updates to add Meta's response in the fourth paragraph.)

Meta Platforms ( META ) stopped an internal research into the mental health effects of its Facebook app after it showed causal proof of negative impacts of usage, Reuters reported Sunday, citing filings in a lawsuit by US school districts against social media platforms, including Meta.

Instead of publishing such findings or pursuing further research, the social media giant called off more work and internally declared that the harmful study findings were driven by the "existing media narrative" around Meta, the news agency reported, citing court documents.

The company said that it stopped the study because of its flawed methodology, Reuters reported, citing Meta spokesman Andy Stone.

"We strongly disagree with these allegations, which rely on cherry-picked quotes and misinformed opinions in an attempt to present a deliberately misleading picture," the company said in a note emailed to MT Newswires. "The full record will show that for over a decade, we have listened to parents, researched issues that matter most, and made real changes to protect teens."

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis
Jun 20, 2024
12:27 PM EDT, 06/20/2024 (MT Newswires) -- AbbVie ( ABBV ) said late Tuesday that Skyrizi has received approval from the US Food and Drug Administration for adults with moderately to severely active ulcerative colitis, expanding its portfolio across inflammatory bowel disease. The company said data showed that the goals of clinical remission and endoscopic improvement were achieved with Skyrizi....
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Jun 20, 2024
Cannabinoids-based pharmaceutical company MediPharm Labs Corp ( MEDIF ). (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to acquire the exclusive rights for advanced cannabis products. Under the deal, current Remidose customers will be serviced through MediPharm ( MEDIF ) starting August 2024, including Canadian direct-to-patient medical platforms and international medical...
Snapchat owner to pay $15 mln to settle California sex bias probe
Snapchat owner to pay $15 mln to settle California sex bias probe
Jun 20, 2024
June 20 (Reuters) - Snapchat owner Snap has agreed to pay $15 million to settle a California civil rights agency's claims that the tech company paid women less than men, subjected female workers to sexual harassment and retaliated against them for complaining. The California Civil Rights Department announced the settlement, which is subject to court approval, in a release on...
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Jun 20, 2024
Thursday, Jazz Pharmaceuticals plc ( JAZZ )  released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). The Phase 2b study assessed the efficacy and safety of suvecaltamide in a once-daily oral dose of 10, 20, and 30mg or placebo....
Copyright 2023-2026 - www.financetom.com All Rights Reserved